Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma — Stella

Home/Renal Cell Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Renal Cell Carcinoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania

Key details

Phase

Very early testing

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

Merck Sharp & Dohme LLC

Enrollment target

~30 participants

Started

May 2023

Primary completion

June 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

18 Years and older

Last updated March 2026